{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:13:26Z","timestamp":1777994006979,"version":"3.51.4"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"DOI":"10.7759\/cureus.108302","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:49:36Z","timestamp":1777992576000},"source":"Crossref","is-referenced-by-count":0,"title":["Precision Medicine in Treating Lung Cancer: A Narrative Review on Treatments Targeting Oncogenic Genetic Mutations"],"prefix":"10.7759","author":[{"given":"Eesha","family":"Chitneni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adwaith","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Confidence Obianuju","family":"Okorie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie T","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakriti","family":"Arya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenica","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Yasin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Cereser Prado de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshan","family":"Afshan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vyapti A","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter A","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol. 2023, 20:624-39. 10.1038\/s41571-023-00798-3","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad097","article-title":"Urgent need to mitigate disparities in federal funding for cancer research","volume":"115","author":"Haghighat S","year":"2023","unstructured":"Haghighat S, Jiang C, El-Rifai W, Zaika A, Goldberg DS, Kumar S. Urgent need to mitigate disparities in federal funding for cancer research. J Natl Cancer Inst. 2023, 115:1220-3. 10.1093\/jnci\/djad097","journal-title":"J Natl Cancer Inst"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai AA","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021, 398:535-54. 10.1016\/s0140-6736(21)00312-3","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2224-5820.2014.06.01","article-title":"Targeted therapy for lung cancer: present and future","volume":"3","author":"Aggarwal C","year":"2014","unstructured":"Aggarwal C. Targeted therapy for lung cancer: present and future. Ann Palliat Med. 2014, 3:229-35. 10.3978\/j.issn.2224-5820.2014.06.01","journal-title":"Ann Palliat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li Y","year":"2023","unstructured":"Li Y, Yan B, He S. Advances and challenges in the treatment of lung cancer. Biomed Pharmacother. 2023, 169:115891. 10.1016\/j.biopha.2023.115891","journal-title":"Biomed Pharmacother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31823e701a","article-title":"Targeted therapies for lung cancer: clinical experience and novel agents","volume":"17","author":"Larsen JE","year":"2011","unstructured":"Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J. 2011, 17:512-27. 10.1097\/PPO.0b013e31823e701a","journal-title":"Cancer J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030353","article-title":"Emerging targeted therapies in non-small-cell lung cancer (NSCLC)","volume":"17","author":"Mina SA","year":"2025","unstructured":"Mina SA, Shanshal M, Leventakos K, Parikh K. Emerging targeted therapies in non-small-cell lung cancer (NSCLC). Cancers (Basel). 2025, 17:10.3390\/cancers17030353","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01299-6","article-title":"Lung cancer treatment: 20 years of progress","volume":"403","author":"The Lancet","year":"2024","unstructured":"The Lancet. Lung cancer treatment: 20 years of progress. Lancet. 2024, 403:2663. 10.1016\/s0140-6736(24)01299-6","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3892\/or.2023.8675","article-title":"The advance of the third\u2011generation EGFR\u2011TKI in the treatment of non\u2011small cell lung cancer (Review)","volume":"51","author":"Cheng Z","year":"2024","unstructured":"Cheng Z, Cui H, Wang Y, et al.. The advance of the third\u2011generation EGFR\u2011TKI in the treatment of non\u2011small cell lung cancer (Review). Oncol Rep. 2024, 51:10.3892\/or.2023.8675","journal-title":"Oncol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-619","article-title":"Advancements of ALK inhibition of non-small cell lung cancer: a literature review","volume":"12","author":"Zia V","year":"2023","unstructured":"Zia V, Lengyel CG, Tajima CC, de Mello RA. Advancements of ALK inhibition of non-small cell lung cancer: a literature review. Transl Lung Cancer Res. 2023, 12:1563-74. 10.21037\/tlcr-22-619","journal-title":"Transl Lung Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/17534666211066064","article-title":"KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block","volume":"16","author":"Garcia-Robledo JE","year":"2022","unstructured":"Garcia-Robledo JE, Rosell R, Ru\u00edz-Pati\u00f1o A, et al.. KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. Ther Adv Respir Dis. 2022, 16:17534666211066064. 10.1177\/17534666211066064","journal-title":"Ther Adv Respir Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.014.10028","article-title":"The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution: focus on China","volume":"33","author":"Loomis D","year":"2014","unstructured":"Loomis D, Huang W, Chen G. The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution: focus on China. Chin J Cancer. 2014, 33:189-96. 10.5732\/cjc.014.10028","journal-title":"Chin J Cancer"},{"key":"ref14","article-title":"Man-made Mineral Fibres and Radon","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"1988","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Man-made Mineral Fibres and Radon. International Agency for Research on Cancer, Lyon, France; 1988."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17041457","article-title":"Residential radon and histological types of lung cancer: a meta-analysis of case-control studies","volume":"17","author":"Li C","year":"2020","unstructured":"Li C, Wang C, Yu J, Fan Y, Liu D, Zhou W, Shi T. Residential radon and histological types of lung cancer: a meta-analysis of case-control studies. Int J Environ Res Public Health. 2020, 17:10.3390\/ijerph17041457","journal-title":"Int J Environ Res Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/ede.0b013e318142c8a1","article-title":"Occupational exposures, environmental tobacco smoke, and lung cancer","volume":"18","author":"Veglia F","year":"2007","unstructured":"Veglia F, Vineis P, Overvad K, et al.. Occupational exposures, environmental tobacco smoke, and lung cancer. Epidemiology. 2007, 18:769-75. 10.1097\/ede.0b013e318142c8a1","journal-title":"Epidemiology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.09.004","article-title":"Etiology of lung cancer: evidence from epidemiologic studies","volume":"2","author":"Zou K","year":"2022","unstructured":"Zou K, Sun P, Huang H, et al.. Etiology of lung cancer: evidence from epidemiologic studies. J Natl Cancer Cent. 2022, 2:216-25. 10.1016\/j.jncc.2022.09.004","journal-title":"J Natl Cancer Cent"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.07.998","article-title":"Tobacco smoking and cancer: a brief review of recent epidemiological evidence","volume":"45","author":"Sasco AJ","year":"2004","unstructured":"Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer. 2004, 45:S3-9. 10.1016\/j.lungcan.2004.07.998","journal-title":"Lung Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Kosaka T","year":"2004","unstructured":"Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004, 64:8919-23. 10.1158\/0008-5472.CAN-04-2818","journal-title":"Cancer Res"},{"key":"ref20","article-title":"Personal Habits and Indoor Combustions","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2012","unstructured":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal Habits and Indoor Combustions. International Agency for Research on Cancer, Lyon, France; 2012."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/30.2.289","article-title":"Familial aggregation of lung cancer in humans","volume":"30","author":"Tokuhata GK","year":"1963","unstructured":"Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J Natl Cancer Inst. 1963, 30:289-312. 10.1093\/jnci\/30.2.289","journal-title":"J Natl Cancer Inst"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2351","article-title":"Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population","volume":"44","author":"Dong J","year":"2012","unstructured":"Dong J, Hu Z, Wu C, et al.. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet. 2012, 44:895-9. 10.1038\/ng.2351","journal-title":"Nat Genet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/ng.875","article-title":"A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese","volume":"43","author":"Hu Z","year":"2011","unstructured":"Hu Z, Wu C, Shi Y, et al.. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet. 2011, 43:792-6. 10.1038\/ng.875","journal-title":"Nat Genet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/ng.667","article-title":"Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations","volume":"42","author":"Miki D","year":"2010","unstructured":"Miki D, Kubo M, Takahashi A, et al.. Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet. 2010, 42:893-6. 10.1038\/ng.667","journal-title":"Nat Genet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/ng.109","article-title":"Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1","volume":"40","author":"Amos CI","year":"2008","unstructured":"Amos CI, Wu X, Broderick P, et al.. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008, 40:616-22. 10.1038\/ng.109","journal-title":"Nat Genet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0680","article-title":"Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study","volume":"69","author":"Broderick P","year":"2009","unstructured":"Broderick P, Wang Y, Vijayakrishnan J, et al.. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 2009, 69:6633-41. 10.1158\/0008-5472.CAN-09-0680","journal-title":"Cancer Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/nature06885","article-title":"A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25","volume":"452","author":"Hung RJ","year":"2008","unstructured":"Hung RJ, McKay JD, Gaborieau V, et al.. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008, 452:633-7. 10.1038\/nature06885","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn268","article-title":"Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer","volume":"100","author":"Liu P","year":"2008","unstructured":"Liu P, Vikis HG, Wang D, et al.. Familial aggregation of common sequence variants on 15q24-25.1 in lung cancer. J Natl Cancer Inst. 2008, 100:1326-30. 10.1093\/jnci\/djn268","journal-title":"J Natl Cancer Inst"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nature06846","article-title":"A variant associated with nicotine dependence, lung cancer and peripheral arterial disease","volume":"452","author":"Thorgeirsson TE","year":"2008","unstructured":"Thorgeirsson TE, Geller F, Sulem P, et al.. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008, 452:638-42. 10.1038\/nature06846","journal-title":"Nature"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3892","article-title":"Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes","volume":"49","author":"McKay JD","year":"2017","unstructured":"McKay JD, Hung RJ, Han Y, et al.. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet. 2017, 49:1126-32. 10.1038\/ng.3892","journal-title":"Nat Genet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.09.012","article-title":"A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma","volume":"85","author":"Landi MT","year":"2009","unstructured":"Landi MT, Chatterjee N, Yu K, et al.. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009, 85:679-91. 10.1016\/j.ajhg.2009.09.012","journal-title":"Am J Hum Genet"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds334","article-title":"Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls","volume":"21","author":"Timofeeva MN","year":"2012","unstructured":"Timofeeva MN, Hung RJ, Rafnar T, et al.. Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet. 2012, 21:4980-95. 10.1093\/hmg\/dds334","journal-title":"Hum Mol Genet"},{"key":"ref33","unstructured":"Global Cancer Observatory. Cancer Today: Statistics at a glance, 2022. (2024). Accessed: March 11, 2025: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref35","unstructured":"Global Cancer Observatory. Cancer Today. (2026). Accessed: March 12, 2025: https:\/\/gco.iarc.fr\/en."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30400-0","article-title":"Cancer control in the Pacific: big challenges facing small island states","volume":"20","author":"Sarfati D","year":"2019","unstructured":"Sarfati D, Dyer R, Sam FA, et al.. Cancer control in the Pacific: big challenges facing small island states. Lancet Oncol. 2019, 20:e475-92. 10.1016\/S1470-2045(19)30400-0","journal-title":"Lancet Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2018.7397","article-title":"Lung cancer among women in the United States","volume":"27","author":"Henley SJ","year":"2018","unstructured":"Henley SJ, Gallaway S, Singh SD, O'Neil ME, Buchanan Lunsford N, Momin B, Richards TB. Lung cancer among women in the United States. J Womens Health (Larchmt). 2018, 27:1307-16. 10.1089\/jwh.2018.7397","journal-title":"J Womens Health (Larchmt)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.10.014","article-title":"Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988-2010","volume":"51","author":"Lortet-Tieulent J","year":"2015","unstructured":"Lortet-Tieulent J, Renteria E, Sharp L, et al.. Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988-2010. Eur J Cancer. 2015, 51:1144-63. 10.1016\/j.ejca.2013.10.014","journal-title":"Eur J Cancer"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4415","article-title":"The burden of lung cancer in women compared with men in the US","volume":"9","author":"Jemal A","year":"2023","unstructured":"Jemal A, Schafer EJ, Sung H, Bandi P, Kratzer T, Islami F, Siegel RL. The burden of lung cancer in women compared with men in the US. JAMA Oncol. 2023, 9:1727-8. 10.1001\/jamaoncol.2023.4415","journal-title":"JAMA Oncol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715907","article-title":"Higher lung cancer incidence in young women than young men in the United States","volume":"378","author":"Jemal A","year":"2018","unstructured":"Jemal A, Miller KD, Ma J, et al.. Higher lung cancer incidence in young women than young men in the United States. N Engl J Med. 2018, 378:1999-2009. 10.1056\/NEJMoa1715907","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1759-7714.2010.00011.x","article-title":"Evaluation on the incidence, mortality and tendency of lung cancer in China","volume":"1","author":"Chen W","year":"2010","unstructured":"Chen W, Zhang S, Zou X. Evaluation on the incidence, mortality and tendency of lung cancer in China. Thorac Cancer. 2010, 1:35-40. 10.1111\/j.1759-7714.2010.00011.x","journal-title":"Thorac Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/tobaccocontrol-2018-054372","article-title":"Tobacco control and Healthy China 2030","volume":"28","author":"Goodchild M","year":"2019","unstructured":"Goodchild M, Zheng R. Tobacco control and Healthy China 2030. Tob Control. 2019, 28:409-13. 10.1136\/tobaccocontrol-2018-054372","journal-title":"Tob Control"},{"key":"ref43","unstructured":"Lung cancer statistics. (2022). Accessed. March 11, 2025: https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/lung-cancer-statistics\/."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2007.10.004","article-title":"Differences in the influence of tobacco smoking on lung cancer between Japan and the USA: possible explanations for the 'smoking paradox' in Japan","volume":"122","author":"Takahashi I","year":"2008","unstructured":"Takahashi I, Matsuzaka M, Umeda T, et al.. Differences in the influence of tobacco smoking on lung cancer between Japan and the USA: possible explanations for the 'smoking paradox' in Japan. Public Health. 2008, 122:891-6. 10.1016\/j.puhe.2007.10.004","journal-title":"Public Health"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/oem.60.8.584","article-title":"Occupational exposures and lung cancer in New Caledonia","volume":"60","author":"Menvielle G","year":"2003","unstructured":"Menvielle G, Luce D, F\u00e9votte J, et al.. Occupational exposures and lung cancer in New Caledonia. Occup Environ Med. 2003, 60:584-9. 10.1136\/oem.60.8.584","journal-title":"Occup Environ Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a010201","article-title":"Environmental exposure to tremolite and respiratory cancer in New Caledonia: a case-control study","volume":"151","author":"Luce D","year":"2000","unstructured":"Luce D, Bugel I, Goldberg P, et al.. Environmental exposure to tremolite and respiratory cancer in New Caledonia: a case-control study. Am J Epidemiol. 2000, 151:259-65. 10.1093\/oxfordjournals.aje.a010201","journal-title":"Am J Epidemiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-017-0187-6","article-title":"Proportion and clinical features of never-smokers with non-small cell lung cancer","volume":"36","author":"Cho J","year":"2017","unstructured":"Cho J, Choi SM, Lee J, et al.. Proportion and clinical features of never-smokers with non-small cell lung cancer. Chin J Cancer. 2017, 36:20. 10.1186\/s40880-017-0187-6","journal-title":"Chin J Cancer"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.6038","article-title":"Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases","volume":"28","author":"Sun Y","year":"2010","unstructured":"Sun Y, Ren Y, Fang Z, et al.. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010, 28:4616-20. 10.1200\/JCO.2010.29.6038","journal-title":"J Clin Oncol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028204","article-title":"Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers","volume":"6","author":"Li C","year":"2011","unstructured":"Li C, Fang R, Sun Y, et al.. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011, 6:e28204. 10.1371\/journal.pone.0028204","journal-title":"PLoS One"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.05.14","article-title":"Lung cancer in never smokers-the East Asian experience","volume":"7","author":"Zhou F","year":"2018","unstructured":"Zhou F, Zhou C. Lung cancer in never smokers-the East Asian experience. Transl Lung Cancer Res. 2018, 7:450-63. 10.21037\/tlcr.2018.05.14","journal-title":"Transl Lung Cancer Res"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2024.100430","article-title":"Uniqueness of lung cancer in Southeast Asia","volume":"27","author":"Noronha V","year":"2024","unstructured":"Noronha V, Budukh A, Chaturvedi P, et al.. Uniqueness of lung cancer in Southeast Asia. Lancet Reg Health Southeast Asia. 2024, 27:100430. 10.1016\/j.lansea.2024.100430","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-005-1254-y","article-title":"Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas","volume":"446","author":"Soung YH","year":"2005","unstructured":"Soung YH, Lee JW, Kim SY, et al.. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 2005, 446:483-8. 10.1007\/s00428-005-1254-y","journal-title":"Virchows Arch"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.011.10106","article-title":"East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians","volume":"30","author":"Zhou W","year":"2011","unstructured":"Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011, 30:287-92. 10.5732\/cjc.011.10106","journal-title":"Chin J Cancer"},{"key":"ref54","article-title":"Clinical significance of ras oncogene activation in human lung cancer","volume":"52","author":"Rodenhuis S","year":"1992","unstructured":"Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res. 1992, 52:2665s-9s.","journal-title":"Cancer Res"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-56806-0_40","article-title":"Risk and protection for lung cancer among Native Hawaiians and Pacific Islanders","author":"Wills TA","year":"2024","unstructured":"Wills TA, Kaholokula JK, Pokhrel P, Cassel K. Risk and protection for lung cancer among Native Hawaiians and Pacific Islanders. Indigenous and Tribal Peoples and Cancer. Garvey G (ed): Springer, Cham; 2024. 10.1007\/978-3-031-56806-0_40"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-015-0358-9","article-title":"Gefitinib: a review of its use in adults with advanced non-small cell lung cancer","volume":"10","author":"Dhillon S","year":"2015","unstructured":"Dhillon S. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Target Oncol. 2015, 10:153-70. 10.1007\/s11523-015-0358-9","journal-title":"Target Oncol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220931926","article-title":"Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings","volume":"26","author":"Harvey RD","year":"2020","unstructured":"Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings. J Oncol Pharm Pract. 2020, 26:1461-74. 10.1177\/1078155220931926","journal-title":"J Oncol Pharm Pract"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0535","article-title":"Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application","volume":"15","author":"Sun H","year":"2019","unstructured":"Sun H, Wu YL. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. Future Oncol. 2019, 15:2769-77. 10.2217\/fon-2018-0535","journal-title":"Future Oncol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101260","article-title":"Consensus on the lung cancer management after third-generation EGFR-TKI resistance","volume":"53","author":"Zhou Q","year":"2024","unstructured":"Zhou Q, Zhao H, Lu S, et al.. Consensus on the lung cancer management after third-generation EGFR-TKI resistance. Lancet Reg Health West Pac. 2024, 53:101260. 10.1016\/j.lanwpc.2024.101260","journal-title":"Lancet Reg Health West Pac"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1367204","article-title":"The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation","volume":"14","author":"Man X","year":"2024","unstructured":"Man X, Sun X, Chen C, Xiang Y, Zhang J, Yang L. The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation. Front Oncol. 2024, 14:1367204. 10.3389\/fonc.2024.1367204","journal-title":"Front Oncol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9011","article-title":"BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1\/2 SYMPHONY study","volume":"41","author":"Elamin YY","year":"2023","unstructured":"Elamin YY, Nagasaka M, Shum E, et al.. BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1\/2 SYMPHONY study. J Clin Oncol. 2023, 41:9011. 10.1200\/JCO.2023.41.16_suppl.9011","journal-title":"J Clin Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-CT184","article-title":"Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1\/2 SYMPHONY study","volume":"82","author":"Shum E","year":"2022","unstructured":"Shum E, Elamin Y, Reckamp KL, et al.. Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1\/2 SYMPHONY study. Cancer Res. 2022, 82:CT184. 10.1158\/1538-7445.AM2022-CT184","journal-title":"Cancer Res"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3901","article-title":"BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non-small cell lung cancer","volume":"29","author":"Lim SM","year":"2023","unstructured":"Lim SM, Fujino T, Kim C, et al.. BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non-small cell lung cancer. Clin Cancer Res. 2023, 29:3004-16. 10.1158\/1078-0432.CCR-22-3901","journal-title":"Clin Cancer Res"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-406","article-title":"Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges","volume":"13","author":"Su C","year":"2024","unstructured":"Su C, Sun SY. Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges. Transl Cancer Res. 2024, 13:3929-34. 10.21037\/tcr-24-406","journal-title":"Transl Cancer Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027954","article-title":"Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: a meta-analysis","volume":"100","author":"Luo W","year":"2021","unstructured":"Luo W, Li Y, Ye F, Li Q, Zhang G, Li J, Li X. Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: a meta-analysis. Medicine (Baltimore). 2021, 100:e27954. 10.1097\/MD.0000000000027954","journal-title":"Medicine (Baltimore)"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou C","year":"2023","unstructured":"Zhou C, Tang KJ, Cho BC, et al.. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023, 389:2039-51. 10.1056\/NEJMoa2306441","journal-title":"N Engl J Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102393","article-title":"A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)","volume":"106","author":"Abuhelwa Z","year":"2022","unstructured":"Abuhelwa Z, Alloghbi A, Nagasaka M. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022, 106:102393. 10.1016\/j.ctrv.2022.102393","journal-title":"Cancer Treat Rev"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231193726","article-title":"Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"15","author":"Li YS","year":"2023","unstructured":"Li YS, Jie GL, Wu YL. Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer. Ther Adv Med Oncol. 2023, 15:17588359231193726. 10.1177\/17588359231193726","journal-title":"Ther Adv Med Oncol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett Z","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, Planchard D. Acquired resistance mechanisms to osimertinib: the constant battle. Cancer Treat Rev. 2023, 116:102557. 10.1016\/j.ctrv.2023.102557","journal-title":"Cancer Treat Rev"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1615\/JEnvironPatholToxicolOncol.2022042281","article-title":"PI3K\/Akt\/mTOR pathways inhibitors with potential prospects in non-small-cell lung cancer","volume":"41","author":"Alharbi KS","year":"2022","unstructured":"Alharbi KS, Shaikh MA, Almalki WH, et al.. PI3K\/Akt\/mTOR pathways inhibitors with potential prospects in non-small-cell lung cancer. J Environ Pathol Toxicol Oncol. 2022, 41:85-102. 10.1615\/JEnvironPatholToxicolOncol.2022042281","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01025-7","article-title":"MEK inhibitors for the treatment of non-small cell lung cancer","volume":"14","author":"Han J","year":"2021","unstructured":"Han J, Liu Y, Yang S, Wu X, Li H, Wang Q. MEK inhibitors for the treatment of non-small cell lung cancer. J Hematol Oncol. 2021, 14:1. 10.1186\/s13045-020-01025-7","journal-title":"J Hematol Oncol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-024-00565-9","article-title":"Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation","volume":"13","author":"Huang S","year":"2024","unstructured":"Huang S, Long Y, Gao Y, et al.. Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation. Exp Hematol Oncol. 2024, 13:97. 10.1186\/s40164-024-00565-9","journal-title":"Exp Hematol Oncol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241227677","article-title":"Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis","volume":"16","author":"Zhou G","year":"2024","unstructured":"Zhou G, Guo L, Xu J, Tang K, Chen J. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis. Ther Adv Med Oncol. 2024, 16:17588359241227677. 10.1177\/17588359241227677","journal-title":"Ther Adv Med Oncol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01921","article-title":"Combination of osimertinib and vascular endothelial growth factor receptor inhibitors for EGFR-mutated non-small cell lung cancer: old or new regimen?","volume":"43","author":"Kenmotsu H","year":"2025","unstructured":"Kenmotsu H. Combination of osimertinib and vascular endothelial growth factor receptor inhibitors for EGFR-mutated non-small cell lung cancer: old or new regimen?. J Clin Oncol. 2025, 43:369-72. 10.1200\/JCO-24-01921","journal-title":"J Clin Oncol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard GR","year":"2020","unstructured":"Oxnard GR, Yang JC, Yu H, et al.. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020, 31:507-16. 10.1016\/j.annonc.2020.01.013","journal-title":"Ann Oncol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0776-2","article-title":"Role and targeting of anaplastic lymphoma kinase in cancer","volume":"17","author":"Della Corte CM","year":"2018","unstructured":"Della Corte CM, Viscardi G, Di Liello R, et al.. Role and targeting of anaplastic lymphoma kinase in cancer. Mol Cancer. 2018, 17:30. 10.1186\/s12943-018-0776-2","journal-title":"Mol Cancer"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian D","year":"2014","unstructured":"Kazandjian D, Blumenthal GM, Chen HY, et al.. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist. 2014, 19:e5-11. 10.1634\/theoncologist.2014-0241","journal-title":"Oncologist"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101191","article-title":"Will the clinical development of 4th-generation \"double mutant active\" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?","volume":"14","author":"Ou SI","year":"2021","unstructured":"Ou SI, Nagasaka M, Brazel D, Hou Y, Zhu VW. Will the clinical development of 4th-generation \"double mutant active\" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. Transl Oncol. 2021, 14:101191. 10.1016\/j.tranon.2021.101191","journal-title":"Transl Oncol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13195023","article-title":"MET amplification in non-small cell lung cancer (NSCLC)-a consecutive evaluation using next-generation sequencing (NGS) in a real-world setting","volume":"13","author":"Schubart C","year":"2021","unstructured":"Schubart C, St\u00f6hr R, T\u00f6gel L, et al.. MET amplification in non-small cell lung cancer (NSCLC)-a consecutive evaluation using next-generation sequencing (NGS) in a real-world setting. Cancers (Basel). 2021, 13:10.3390\/cancers13195023","journal-title":"Cancers (Basel)"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194708","article-title":"Savolitinib: a promising targeting agent for cancer","volume":"15","author":"Lee TS","year":"2023","unstructured":"Lee TS, Kim JY, Lee MH, et al.. Savolitinib: a promising targeting agent for cancer. Cancers (Basel). 2023, 15:10.3390\/cancers15194708","journal-title":"Cancers (Basel)"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107816","article-title":"Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence","volume":"192","author":"Nadal E","year":"2024","unstructured":"Nadal E, Rifi N, Kane S, et al.. Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence. Lung Cancer. 2024, 192:107816. 10.1016\/j.lungcan.2024.107816","journal-title":"Lung Cancer"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1111\/febs.17032","article-title":"CD74-ROS1 L2026M mutant enhances autophagy through the MEK\/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells","volume":"291","author":"Xu X","year":"2024","unstructured":"Xu X, Li Y, Xu R, Meng Y, Li Z, Zuo D, Wu Y. CD74-ROS1 L2026M mutant enhances autophagy through the MEK\/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells. FEBS J. 2024, 291:1199-219. 10.1111\/febs.17032","journal-title":"FEBS J"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050748","article-title":"Population-adjusted indirect treatment comparisons of repotrectinib among patients with ROS1+ NSCLC","volume":"17","author":"Wolf J","year":"2025","unstructured":"Wolf J, Goring S, Lee A, et al.. Population-adjusted indirect treatment comparisons of repotrectinib among patients with ROS1+ NSCLC. Cancers (Basel). 2025, 17:10.3390\/cancers17050748","journal-title":"Cancers (Basel)"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101090","article-title":"Drug development and evidence for lung cancer targeted therapy in Eastern Asia","volume":"49","author":"Maggie Liu SY","year":"2024","unstructured":"Maggie Liu SY, Jin ZY, Deng JY, et al.. Drug development and evidence for lung cancer targeted therapy in Eastern Asia. Lancet Reg Health West Pac. 2024, 49:101090. 10.1016\/j.lanwpc.2024.101090","journal-title":"Lancet Reg Health West Pac"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1357898","article-title":"Resistance to KRAS inhibition in advanced non-small cell lung cancer","volume":"14","author":"Sreter KB","year":"2024","unstructured":"Sreter KB, Catarata MJ, von Laffert M, Frille A. Resistance to KRAS inhibition in advanced non-small cell lung cancer. Front Oncol. 2024, 14:1357898. 10.3389\/fonc.2024.1357898","journal-title":"Front Oncol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation","volume":"11","author":"Tanaka N","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, et al.. Clinical acquired resistance to KRAS(G12C) inhibition through a novel KRAS Switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021, 11:1913-22. 10.1158\/2159-8290.CD-21-0365","journal-title":"Cancer Discov"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets M","year":"2021","unstructured":"Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021, 6:100260. 10.1016\/j.esmoop.2021.100260","journal-title":"ESMO Open"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102520","article-title":"Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges","volume":"114","author":"Yu Y","year":"2023","unstructured":"Yu Y, Yang Y, Li H, Fan Y. Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges. Cancer Treat Rev. 2023, 114:102520. 10.1016\/j.ctrv.2023.102520","journal-title":"Cancer Treat Rev"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study","volume":"43","author":"Heymach JV","year":"2025","unstructured":"Heymach JV, Opdam F, Barve M, et al.. HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study. J Clin Oncol. 2025, 43:1337-47. 10.1200\/JCO-24-01727","journal-title":"J Clin Oncol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051154","article-title":"Targeting the fibroblast growth factor receptor (FGFR) family in lung cancer","volume":"10","author":"Pacini L","year":"2021","unstructured":"Pacini L, Jenks AD, Lima NC, Huang PH. Targeting the fibroblast growth factor receptor (FGFR) family in lung cancer. Cells. 2021, 10:10.3390\/cells10051154","journal-title":"Cells"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.10.005","article-title":"The efficacy of pemigatinib in advanced NSCLC with FGFR aberration: case report","volume":"25","author":"Gao M","year":"2024","unstructured":"Gao M, Wang L, Jing F, Zhang F, Tao H, Hu Y. The efficacy of pemigatinib in advanced NSCLC with FGFR aberration: case report. Clin Lung Cancer. 2024, 25:e62-6. 10.1016\/j.cllc.2023.10.005","journal-title":"Clin Lung Cancer"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00533","article-title":"A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial)","volume":"43","author":"Le X","year":"2025","unstructured":"Le X, Patel JD, Shum E, et al.. A multicenter open-label randomized phase II study of osimertinib with and without ramucirumab in tyrosine kinase inhibitor-na\u00efve EGFR-mutant metastatic non-small cell lung cancer (RAMOSE trial). J Clin Oncol. 2025, 43:403-11. 10.1200\/JCO.24.00533","journal-title":"J Clin Oncol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030638","article-title":"The interplay between heat shock proteins and cancer pathogenesis: a novel strategy for cancer therapeutics","volume":"16","author":"Somu P","year":"2024","unstructured":"Somu P, Mohanty S, Basavegowda N, Yadav AK, Paul S, Baek KH. The interplay between heat shock proteins and cancer pathogenesis: a novel strategy for cancer therapeutics. Cancers (Basel). 2024, 16:10.3390\/cancers16030638","journal-title":"Cancers (Basel)"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis","volume":"17","author":"Planchard D","year":"2022","unstructured":"Planchard D, Besse B, Groen HJ, et al.. Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. J Thorac Oncol. 2022, 17:103-15. 10.1016\/j.jtho.2021.08.011","journal-title":"J Thorac Oncol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1375136","article-title":"Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"15","author":"Huang S","year":"2024","unstructured":"Huang S, Huang Z, Huang X, Luo R, Liang W, Qin T. Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis. Front Immunol. 2024, 15:1375136. 10.3389\/fimmu.2024.1375136","journal-title":"Front Immunol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann MD","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, et al.. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019, 381:2020-31. 10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-2117-6","article-title":"Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs","volume":"73","author":"Bayliss R","year":"2016","unstructured":"Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cell Mol Life Sci. 2016, 73:1209-24. 10.1007\/s00018-015-2117-6","journal-title":"Cell Mol Life Sci"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung cancer: will expectations finally be met?","volume":"12","author":"Drilon A","year":"2017","unstructured":"Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in lung cancer: will expectations finally be met?. J Thorac Oncol. 2017, 12:15-26. 10.1016\/j.jtho.2016.10.014","journal-title":"J Thorac Oncol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863043","article-title":"BRAF-mutated non-small cell lung cancer: current treatment status and future perspective","volume":"12","author":"Yan N","year":"2022","unstructured":"Yan N, Guo S, Zhang H, Zhang Z, Shen S, Li X. BRAF-mutated non-small cell lung cancer: current treatment status and future perspective. Front Oncol. 2022, 12:863043. 10.3389\/fonc.2022.863043","journal-title":"Front Oncol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174155","article-title":"HER2 in non-small cell lung cancer: a review of emerging therapies","volume":"14","author":"Uy NF","year":"2022","unstructured":"Uy NF, Merkhofer CM, Baik CS. HER2 in non-small cell lung cancer: a review of emerging therapies. Cancers (Basel). 2022, 14:10.3390\/cancers14174155","journal-title":"Cancers (Basel)"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.116051","article-title":"Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals","volume":"264","author":"Sun JG","year":"2024","unstructured":"Sun JG, Nie P, Herdewijn P, Li XJ. Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals. Eur J Med Chem. 2024, 264:116051. 10.1016\/j.ejmech.2023.116051","journal-title":"Eur J Med Chem"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101077","article-title":"Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer","volume":"59","author":"Lin QX","year":"2025","unstructured":"Lin QX, Song WW, Xie WX, et al.. Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer. Neoplasia. 2025, 59:101077. 10.1016\/j.neo.2024.101077","journal-title":"Neoplasia"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02012-z","article-title":"DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy","volume":"23","author":"Su PL","year":"2024","unstructured":"Su PL, Chakravarthy K, Furuya N, et al.. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Mol Cancer. 2024, 23:97. 10.1186\/s12943-024-02012-z","journal-title":"Mol Cancer"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1504139","article-title":"Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions","volume":"14","author":"Ding J","year":"2024","unstructured":"Ding J, Yeong C. Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions. Front Oncol. 2024, 14:1504139. 10.3389\/fonc.2024.1504139","journal-title":"Front Oncol"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.05.02","article-title":"Emerging application of genomics-guided therapeutics in personalized lung cancer treatment","volume":"6","author":"Zaman A","year":"2018","unstructured":"Zaman A, Bivona TG. Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Ann Transl Med. 2018, 6:160. 10.21037\/atm.2018.05.02","journal-title":"Ann Transl Med"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315056","article-title":"Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance","volume":"23","author":"Wu J","year":"2022","unstructured":"Wu J, Lin Z. Non-small cell lung cancer targeted therapy: drugs and mechanisms of drug resistance. Int J Mol Sci. 2022, 23:10.3390\/ijms232315056","journal-title":"Int J Mol Sci"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1387345","article-title":"Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives","volume":"14","author":"Zhang H","year":"2024","unstructured":"Zhang H, Zhang Y, Zhu Y, Dong T, Liu Z. Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives. Front Oncol. 2024, 14:1387345. 10.3389\/fonc.2024.1387345","journal-title":"Front Oncol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020504","article-title":"Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer","volume":"15","author":"Chhouri H","year":"2023","unstructured":"Chhouri H, Alexandre D, Grumolato L. Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer. Cancers (Basel). 2023, 15:10.3390\/cancers15020504","journal-title":"Cancers (Basel)"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051206","article-title":"Epidermal growth factor receptor expression and resistance patterns to targeted therapy in non-small cell lung cancer: a review","volume":"10","author":"Karlsen EA","year":"2021","unstructured":"Karlsen EA, Kahler S, Tefay J, Joseph SR, Simpson F. Epidermal growth factor receptor expression and resistance patterns to targeted therapy in non-small cell lung cancer: a review. Cells. 2021, 10:10.3390\/cells10051206","journal-title":"Cells"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.02.006","article-title":"Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies","volume":"65","author":"Lim SM","year":"2018","unstructured":"Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018, 65:1-10. 10.1016\/j.ctrv.2018.02.006","journal-title":"Cancer Treat Rev"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam SS","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al.. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020, 382:41-50. 10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.08.30","article-title":"Mechanisms of resistance to osimertinib","volume":"12","author":"Lazzari C","year":"2020","unstructured":"Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Mechanisms of resistance to osimertinib. J Thorac Dis. 2020, 12:2851-8. 10.21037\/jtd.2019.08.30","journal-title":"J Thorac Dis"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok TS","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, et al.. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017, 376:629-40. 10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.064","article-title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou VA","year":"2018","unstructured":"Papadimitrakopoulou VA, Wu YL, Han JY, et al.. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2018, 29:741. 10.1093\/annonc\/mdy424.064","journal-title":"Ann Oncol"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam SS","year":"2018","unstructured":"Ramalingam SS, Cheng Y, Zhou C, et al.. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol. 2018, 29:740. 10.1093\/annonc\/mdy424.063","journal-title":"Ann Oncol"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa K","year":"2012","unstructured":"Takezawa K, Pirazzoli V, Arcila ME, et al.. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012, 2:922-33. 10.1158\/2159-8290.CD-12-0108","journal-title":"Cancer Discov"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-186","article-title":"Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy","volume":"9","author":"Suda K","year":"2020","unstructured":"Suda K, Mitsudomi T. Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy. Transl Lung Cancer Res. 2020, 9:2618-28. 10.21037\/tlcr-20-186","journal-title":"Transl Lung Cancer Res"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100023","article-title":"Oncogenic fusions may be frequently present at resistance of EGFR tyrosine kinase inhibitors in patients with NSCLC: a brief report","volume":"1","author":"Enrico D","year":"2020","unstructured":"Enrico D, Lacroix L, Chen J, et al.. Oncogenic fusions may be frequently present at resistance of EGFR tyrosine kinase inhibitors in patients with NSCLC: a brief report. JTO Clin Res Rep. 2020, 1:100023. 10.1016\/j.jtocrr.2020.100023","journal-title":"JTO Clin Res Rep"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221079125","article-title":"Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models","volume":"14","author":"Lim SM","year":"2022","unstructured":"Lim SM, Yang SD, Lim S, et al.. Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models. Ther Adv Med Oncol. 2022, 14:17588359221079125. 10.1177\/17588359221079125","journal-title":"Ther Adv Med Oncol"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models","volume":"75","author":"Eberlein CA","year":"2015","unstructured":"Eberlein CA, Stetson D, Markovets AA, et al.. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015, 75:2489-500. 10.1158\/0008-5472.CAN-14-3167","journal-title":"Cancer Res"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2310","article-title":"Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients","volume":"24","author":"Yang Z","year":"2018","unstructured":"Yang Z, Yang N, Ou Q, et al.. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018, 24:3097-107. 10.1158\/1078-0432.CCR-17-2310","journal-title":"Clin Cancer Res"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux N","year":"2019","unstructured":"Marcoux N, Gettinger SN, O'Kane G, et al.. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019, 37:278-85. 10.1200\/JCO.18.01585","journal-title":"J Clin Oncol"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.011","article-title":"Primary resistance to osimertinib due to SCLC transformation: issue of T790M determination on liquid re-biopsy","volume":"115","author":"Minari R","year":"2018","unstructured":"Minari R, Bordi P, Del Re M, et al.. Primary resistance to osimertinib due to SCLC transformation: issue of T790M determination on liquid re-biopsy. Lung Cancer. 2018, 115:21-7. 10.1016\/j.lungcan.2017.11.011","journal-title":"Lung Cancer"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0457-8","article-title":"TGF\u03b22-mediated epithelial-mesenchymal transition and NF-\u03baB pathway activation contribute to osimertinib resistance","volume":"42","author":"Jiang XM","year":"2021","unstructured":"Jiang XM, Xu YL, Yuan LW, et al.. TGF\u03b22-mediated epithelial-mesenchymal transition and NF-\u03baB pathway activation contribute to osimertinib resistance. Acta Pharmacol Sin. 2021, 42:451-9. 10.1038\/s41401-020-0457-8","journal-title":"Acta Pharmacol Sin"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.07.007","article-title":"Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo","volume":"49","author":"Xie M","year":"2013","unstructured":"Xie M, He CS, Wei SH, Zhang L. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur J Cancer. 2013, 49:3559-72. 10.1016\/j.ejca.2013.07.007","journal-title":"Eur J Cancer"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13906","article-title":"Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer","volume":"12","author":"Qin Q","year":"2021","unstructured":"Qin Q, Li X, Liang X, Zeng L, Wang J, Sun L, Zhong D. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer. Thorac Cancer. 2021, 12:1708-15. 10.1111\/1759-7714.13906","journal-title":"Thorac Cancer"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0482-y","article-title":"Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer","volume":"38","author":"Yochum ZA","year":"2019","unstructured":"Yochum ZA, Cades J, Wang H, et al.. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 2019, 38:656-70. 10.1038\/s41388-018-0482-y","journal-title":"Oncogene"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele RC","year":"2012","unstructured":"Doebele RC, Pilling AB, Aisner DL, et al.. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012, 18:1472-82. 10.1158\/1078-0432.CCR-11-2906","journal-title":"Clin Cancer Res"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1159\/000430852","article-title":"Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data","volume":"38","author":"Toyokawa G","year":"2015","unstructured":"Toyokawa G, Seto T. Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol Res Treat. 2015, 38:291-8. 10.1159\/000430852","journal-title":"Oncol Res Treat"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00281","article-title":"Understanding lineage plasticity as a path to targeted therapy failure in EGFR-mutant non-small cell lung cancer","volume":"11","author":"Shaurova T","year":"2020","unstructured":"Shaurova T, Zhang L, Goodrich DW, Hershberger PA. Understanding lineage plasticity as a path to targeted therapy failure in EGFR-mutant non-small cell lung cancer. Front Genet. 2020, 11:281. 10.3389\/fgene.2020.00281","journal-title":"Front Genet"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor JF","year":"2016","unstructured":"Gainor JF, Dardaei L, Yoda S, et al.. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016, 6:1118-33. 10.1158\/2159-8290.CD-16-0596","journal-title":"Cancer Discov"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper AJ","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022, 19:499-514. 10.1038\/s41571-022-00639-9","journal-title":"Nat Rev Clin Oncol"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer","volume":"8","author":"Yoda S","year":"2018","unstructured":"Yoda S, Lin JJ, Lawrence MS, et al.. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 2018, 8:714-29. 10.1158\/2159-8290.CD-17-1256","journal-title":"Cancer Discov"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.25","article-title":"ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies","volume":"7","author":"Poei D","year":"2024","unstructured":"Poei D, Ali S, Ye S, Hsu R. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies. Cancer Drug Resist. 2024, 7:20. 10.20517\/cdr.2024.25","journal-title":"Cancer Drug Resist"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113293","article-title":"Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies","volume":"12","author":"D'Angelo A","year":"2020","unstructured":"D'Angelo A, Sobhani N, Chapman R, et al.. Focus on ROS1-positive non-small cell lung cancer (NSCLC): crizotinib, resistance mechanisms and the newer generation of targeted therapies. Cancers (Basel). 2020, 12:10.3390\/cancers12113293","journal-title":"Cancers (Basel)"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon A","year":"2024","unstructured":"Drilon A, Camidge DR, Lin JJ, et al.. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024, 390:118-31. 10.1056\/NEJMoa2302299","journal-title":"N Engl J Med"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae205","article-title":"Advances and future directions in ROS1 fusion-positive lung cancer","volume":"29","author":"Boulanger MC","year":"2024","unstructured":"Boulanger MC, Schneider JL, Lin JJ. Advances and future directions in ROS1 fusion-positive lung cancer. Oncologist. 2024, 29:943-56. 10.1093\/oncolo\/oyae205","journal-title":"Oncologist"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.11.004","article-title":"HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient","volume":"151","author":"Wang M","year":"2021","unstructured":"Wang M, Zhang D, Wang G, et al.. HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient. Lung Cancer. 2021, 151:106-7. 10.1016\/j.lungcan.2020.11.004","journal-title":"Lung Cancer"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094633","article-title":"RAF and MEK inhibitors in non-small cell lung cancer","volume":"25","author":"Adamopoulos C","year":"2024","unstructured":"Adamopoulos C, Papavassiliou KA, Poulikakos PI, Papavassiliou AG. RAF and MEK inhibitors in non-small cell lung cancer. Int J Mol Sci. 2024, 25:10.3390\/ijms25094633","journal-title":"Int J Mol Sci"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00152","article-title":"Targeting the HGF\/MET axis in cancer therapy: challenges in resistance and opportunities for improvement","volume":"8","author":"Huang X","year":"2020","unstructured":"Huang X, Li E, Shen H, et al.. Targeting the HGF\/MET axis in cancer therapy: challenges in resistance and opportunities for improvement. Front Cell Dev Biol. 2020, 8:152. 10.3389\/fcell.2020.00152","journal-title":"Front Cell Dev Biol"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.11.011","article-title":"The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable","volume":"103","author":"Reungwetwattana T","year":"2017","unstructured":"Reungwetwattana T, Liang Y, Zhu V, Ou SI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer. 2017, 103:27-37. 10.1016\/j.lungcan.2016.11.011","journal-title":"Lung Cancer"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1640","article-title":"Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer","volume":"25","author":"Suzawa K","year":"2019","unstructured":"Suzawa K, Offin M, Lu D, et al.. Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer. Clin Cancer Res. 2019, 25:1248-60. 10.1158\/1078-0432.CCR-18-1640","journal-title":"Clin Cancer Res"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen J","year":"2017","unstructured":"Phallen J, Sausen M, Adleff V, et al.. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017, 9:10.1126\/scitranslmed.aan2415","journal-title":"Sci Transl Med"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress KS","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, et al.. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015, 21:560-2. 10.1038\/nm.3854","journal-title":"Nat Med"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.02.031","article-title":"Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment","volume":"149","author":"Provencio M","year":"2021","unstructured":"Provencio M, Serna-Blasco R, Franco F, et al.. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. Eur J Cancer. 2021, 149:61-72. 10.1016\/j.ejca.2021.02.031","journal-title":"Eur J Cancer"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.387","article-title":"A phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: LiquidLung-O-Cohort 2","volume":"51","author":"Park CK","year":"2019","unstructured":"Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC. A phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: LiquidLung-O-Cohort 2. Cancer Res Treat. 2019, 51:777-87. 10.4143\/crt.2018.387","journal-title":"Cancer Res Treat"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.10.001","article-title":"Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer","volume":"23","author":"Page RD","year":"2022","unstructured":"Page RD, Drusbosky LM, Dada H, et al.. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer. Clin Lung Cancer. 2022, 23:72-81. 10.1016\/j.cllc.2021.10.001","journal-title":"Clin Lung Cancer"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer","volume":"1","author":"Juergens RA","year":"2011","unstructured":"Juergens RA, Wrangle J, Vendetti FP, et al.. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011, 1:598-607. 10.1158\/2159-8290.CD-11-0214","journal-title":"Cancer Discov"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon JJ","year":"2020","unstructured":"Chabon JJ, Hamilton EG, Kurtz DM, et al.. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020, 580:245-51. 10.1038\/s41586-020-2140-0","journal-title":"Nature"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48210-5","article-title":"Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib","volume":"13","author":"Yamaguchi O","year":"2023","unstructured":"Yamaguchi O, Kasahara N, Soda H, et al.. Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. Sci Rep. 2023, 13:20848. 10.1038\/s41598-023-48210-5","journal-title":"Sci Rep"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.078","article-title":"Challenges in the use of targeted therapies in non-small cell lung cancer","volume":"54","author":"Rivera-Concepcion J","year":"2022","unstructured":"Rivera-Concepcion J, Uprety D, Adjei AA. Challenges in the use of targeted therapies in non-small cell lung cancer. Cancer Res Treat. 2022, 54:315-29. 10.4143\/crt.2022.078","journal-title":"Cancer Res Treat"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194562","article-title":"Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance","volume":"14","author":"Ashrafi A","year":"2022","unstructured":"Ashrafi A, Akter Z, Modareszadeh P, et al.. Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance. Cancers (Basel). 2022, 14:10.3390\/cancers14194562","journal-title":"Cancers (Basel)"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s3195","article-title":"Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer","volume":"5","author":"Ricciardi S","year":"2009","unstructured":"Ricciardi S, Tomao S, de Marinis F. Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer. Ther Clin Risk Manag. 2009, 5:781-7. 10.2147\/tcrm.s3195","journal-title":"Ther Clin Risk Manag"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.53876\/001c.73042","article-title":"Lung cancer management in low and middle-income countries - current challenges and potential solutions","volume":"3","author":"Surapaneni M","year":"2023","unstructured":"Surapaneni M, Uprety D. Lung cancer management in low and middle-income countries - current challenges and potential solutions. Int J Cancer Care Deliv. 2023, 3:30-8. 10.53876\/001c.73042","journal-title":"Int J Cancer Care Deliv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/472292-precision-medicine-in-treating-lung-cancer-a-narrative-review-on-treatments-targeting-oncogenic-genetic-mutations","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:49:42Z","timestamp":1777992582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/472292-precision-medicine-in-treating-lung-cancer-a-narrative-review-on-treatments-targeting-oncogenic-genetic-mutations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":154,"URL":"https:\/\/doi.org\/10.7759\/cureus.108302","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}